Literature DB >> 3667160

Drug sensitivity of ten human tumor cell lines compared to mouse leukemia (L1210) cells.

G J Badiner1, R D Hamilton, L H Li, B K Bhuyan.   

Abstract

L1210 leukemia cells, because of their rapid growth rate in suspension culture and high growth fraction, are ideally suited to screen in vitro for cytotoxic compounds. Although L1210 cells may mimic rapidly growing tumors, they have not been effective in selecting agents active against slow growing solid tumors. We expected that cell lines originating from human solid tumors, because of their slower growth rate and lower S phase fraction, would be more drug resistant than L1210. Therefore, we compared ten human tumor cell lines (5 melanomas, 4 colon carcinomas and 1 small cell lung carcinoma) to L1210 growth inhibition by 9 antitumor drugs. Not one human tumor cell line was consistently more resistant to all nine drugs than L1210 when the cells were exposed to drugs for about 2 doubling times. The drug sensitivity of 2 cell lines (L1210 and SK MEL 28) was again determined after a short term (2 hr) exposure and using growth inhibition and cell survival as end points. For both end points these two cell lines exhibited a random pattern of sensitivity to the drugs tested. Cell kill showed an order of sensitivity different than growth inhibition. The implication of these findings for drug-screening is discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3667160     DOI: 10.1007/bf00175291

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  20 in total

1.  Comparison of in vitro methods to determine drug-induced cell lethality.

Authors:  P R Roper; B Drewinko
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

2.  Comparison of different methods of determining cell viability after exposure to cytotoxic compounds.

Authors:  B K Bhuyan; B E Loughman; T J Fraser; K J Day
Journal:  Exp Cell Res       Date:  1976-02       Impact factor: 3.905

3.  Differential growth inhibition of cultured mammalian cells: comparison of clinical antitumour agents and amsacrine derivatives.

Authors:  W R Wilson; S M Tapp; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1984-03

4.  Esterase activity, exclusion of propidium iodide, and proliferation in tumor cells exposed to anticancer agents: phenomena relevant to chemosensitivity determinations.

Authors:  E J Pavlik; R C Flanigan; J R van Nagell; M B Hanson; E S Donaldson; K Keaton; B Doss; J Bartmas; D E Kenady
Journal:  Cancer Invest       Date:  1985       Impact factor: 2.176

Review 5.  In vitro assays in preclinical antineoplastic drug screening.

Authors:  L M Weisenthal
Journal:  Semin Oncol       Date:  1981-12       Impact factor: 4.929

6.  Classification of human colorectal adenocarcinoma cell lines.

Authors:  A Leibovitz; J C Stinson; W B McCombs; C E McCoy; K C Mazur; N D Mabry
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

7.  Modification of chemotherapeutic effects on L1210 cells using hematoporphyrin and light.

Authors:  S P Creekmore; D S Zaharko
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

8.  Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor.

Authors:  G H Heppner; D L Dexter; T DeNucci; F R Miller; P Calabresi
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

9.  Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.

Authors:  M J Staquet; D P Byar; S B Green; M Rozencweig
Journal:  Cancer Treat Rep       Date:  1983-09

10.  Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells.

Authors:  M Herlyn; W H Clark; M J Mastrangelo; D P Guerry; D E Elder; D LaRossa; R Hamilton; E Bondi; R Tuthill; Z Steplewski; H Koprowski
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

View more
  4 in total

Review 1.  Tumor models in drug development.

Authors:  D P Griswold; S D Harrison
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

2.  Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects.

Authors:  B K Bhuyan; K S Smith; E G Adams; T L Wallace; D D Von Hoff; L H Li
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.

Authors:  G J Badiner; B C Moy; K S Smith; W G Tarpley; V E Groppi; B K Bhuyan
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

4.  High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells.

Authors:  Vesa Hongisto; Sandra Jernström; Vidal Fey; John-Patrick Mpindi; Kristine Kleivi Sahlberg; Olli Kallioniemi; Merja Perälä
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.